We are live on ! Find out more
IKT icon

Inhibikase Therapeutics
IKT

14 hedge funds and large institutions have $10.6M invested in Inhibikase Therapeutics in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

990% more capital invested

Capital invested by funds: $975K → $10.6M (+$9.65M)

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

56% more funds holding

Funds holding: 9 → 14 (+5)

13.49% more ownership

Funds ownership: 1.61% → 15.1% (+13%)

Holders
14
Holders Change
+5
Holders Change %
+55.56%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
4
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KC
Kepos Capital
New York
+$3.43M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$2.31M
3
SM
Sabby Management
Florida
+$2.07M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.63M
5
AC
Antara Capital
New York
+$1.23M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$107K
2
Millennium Management
Millennium Management
New York
-$67K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$12K
4
TRCT
Tower Research Capital (TRC)
New York
-$3K

IKT Hedge Fund Activity: Q2 2021 in Review

14 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q2 2021, worth a combined $10.6M — up 990% from $975K a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new IKT positions and 4 closed out — a net gain of 5 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Kepos Capital, opening a new position worth an estimated $3.43M. The largest seller was Citadel Advisors, exiting entirely with an estimated $107K sold.

  • 14 institutional investors held Inhibikase Therapeutics (IKT) as of Q2 2021, up from 9 in Q1 2021.
  • Funds reported $10.6M of Inhibikase Therapeutics stock for Q2 2021, up 990% quarter-over-quarter.
  • 9 funds opened new Inhibikase Therapeutics positions in Q2 2021 and 4 closed out, a net change of +5 holders.
  • The largest Inhibikase Therapeutics buyer in Q2 2021 was Kepos Capital, an estimated $3.43M added.
  • The largest Inhibikase Therapeutics seller in Q2 2021 was Citadel Advisors, an estimated $107K sold.

Based on aggregated 13F filings for Q2 2021.